Kurnit KC, et al. - In this retrospective cohort study of 140 women with stage I or II uterine carcinosarcoma at their institution between March 1990 and June 2016, researchers assessed the impact of clinicopathologic features and adjuvant treatment on survival outcomes. Most patients had stage IA (67%) vs stage IB (21%) or stage II (11%) disease. Adjuvant treatment was received by most patients (63%) in the following forms: vaginal brachytherapy only (14%); whole pelvic radiation therapy only (16%); chemotherapy only (n = 13, 9%); combination chemotherapy and vaginal brachytherapy (15%); combination chemotherapy and whole pelvic radiation (9%). Patients with early-stage uterine carcinosarcoma had worse overall survival in association with advancing age, stage, and the presence of a rhabdomyosarcoma component. They recommend incorporation of these factors in new treatment algorithms beyond stage alone.